Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 32  |  Issue : 3  |  Page : 983-990

Effect of urokinase plasminogen activator receptor (CD87) on patients with de-novo acute myeloid leukemia


1 Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt
2 Clinical Oncology Department and Hospital, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt
3 Department of Clinical Pathology, Shebin El Kom Teaching Hospital, Shebin El Kom, Egypt

Correspondence Address:
Arwa Abd El Hamed Hijii
Al Sadat Street, Shebin El Kom, Menoufia 32511
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_135_18

Rights and Permissions

Objectives The objective of this study was to study the role and the prognostic value of urokinase-type plasminogen activator receptor (uPAR) (CD87) expression in patients with de-novo acute myeloid leukemia (AML). Background The physiological function of the uPAR (CD87) is concerned in various biological processes and signal transduction such as cancer metastasis, angiogenesis, cell migration, and wound healing. The uPAR is expressed in most solid cancer and in several hematological malignancies including myeloproliferative disease, acute leukemia (AML, acute lymphocytic leukemia), and multiple myeloma. Patients and methods This study was conducted on 52 newly diagnosed patients with AML and 20 age-matched and sex-matched healthy individuals as a control group. Full history taking, clinical examination, and laboratory investigations were done for all patients. Expression of CD87 was evaluated by flow cytometric analysis. Results Positive CD87 expression (CD87+) was significantly higher in patients with AML than in healthy individuals. The highest incidence of CD87+ was found in acute myelomonocytic leukemia and acute monoblastic leukemia (M4/M5). High CD87+ expression in patients with AML predicted poor response to therapy, poor outcome, and shorter overall survival rate. Conclusion The high expression of CD87 displays a negative prognostic effect on patients with AML regarding outcome, survival rate, and response to chemotherapy. However, more studies are required to elucidate its role as a target therapy for those patients as its expression is highly restricted to tumor cells.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed30    
    Printed0    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal